MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ProNAi Therapeutics Company Profile (NASDAQ:DNAI)

Consensus Ratings for ProNAi Therapeutics (NASDAQ:DNAI) (?)
Ratings Breakdown: 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $19.88 (908.88% upside)

Analysts' Ratings History for ProNAi Therapeutics (NASDAQ:DNAI)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016WedbushDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016SunTrustDowngradeBuy -> Neutral$25.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupDowngradeBuy -> Hold$22.00 -> $4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Bank of AmericaInitiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for ProNAi Therapeutics (NASDAQ:DNAI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/19/2016        
5/10/2016Q1($0.42)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.58)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.48)($11.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/21/2015Q215($104.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ProNAi Therapeutics (NASDAQ:DNAI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.54)($0.39)($0.44)
Q2 20163($0.41)($0.37)($0.38)
Q3 20163($0.33)($0.13)($0.26)
Q4 20163($0.31)($0.13)($0.24)
(Data provided by Zacks Investment Research)
Dividend History for ProNAi Therapeutics (NASDAQ:DNAI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ProNAi Therapeutics (NASDAQ:DNAI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/22/2016Wendy ChapmanSVPSell3,000$7.01$21,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Wendy ChapmanSVPSell3,000$7.06$21,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Wendi RodiguezainsiderSell3,000$9.86$29,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Wendy ChapmanSVPSell5,000$9.39$46,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Nicholas GloverCEOSell5,000$10.04$50,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016Chandra D. LovejoySVPSell20,973$11.29$236,785.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015Orbimed Advisors LlcDirectorBuy175,000$17.00$2,975,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2015Vivo Ventures Vii, LlcInsiderBuy220,000$17.00$3,740,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ProNAi Therapeutics (NASDAQ:DNAI)
DateHeadline
06/24/16 10:24 AMPrice Target Update on ProNAi Therapeutics (NASDAQ:DNAI) - Trade Calls
06/23/16 08:39 PMProNAi Therapeutics Inc (NASDAQ:DNAI) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 02:34 PMInvestor News: Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over potential Violations of Securities Laws - GroundReport
06/22/16 03:47 PMProNAi Therapeutics (NASDAQ:DNAI) Analyst Rating Consensus - TheFounders Daily
06/22/16 08:20 AMInvestor News: Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over potential Violations of Securities Laws
06/21/16 03:28 PMPRONAI THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/21/16 03:17 PMPRONAI THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 09:53 AMThis Weeks Broker Views For ProNAi Therapeutics, Inc. (DNAI) - Fiscal Standard
06/17/16 08:55 AMLatest ProNAi Therapeutics, Inc. (NASDAQ:DNAI) Target Price Suggests Stock Is Worth $11.63/Share - iStreetWire
06/17/16 08:55 AMAnalyst Recommendations: Liberty Ventures (NASDAQ:LVNTA), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/15/16 03:44 PMTwo Movers inside Analysts Radar: GLOBAL BLOOD THERAPEUTICS, INC. (NASDAQ:GBT) , ProNAi Therapeutics ... - Street Updates
06/15/16 03:44 PMAnalyst Recommended Stocks: Duke Realty Corporation (NYSE:DRE), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/15/16 03:44 PMStock's Earnings Analysis: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), Prospect Capital Corporation (NASDAQ:PSEC) - Beacon Chronicle
06/14/16 03:31 PMInvestor Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over Possible Violations of Securities Laws
06/13/16 08:42 AMBiotech New Lows: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), Chimerix, Inc. (NASDAQ:CMRX), ImmunoGen, Inc ... - KC Register
06/13/16 08:42 AMHot Stock under Consideration: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/10/16 10:53 AMWeekly roundup: Get your baseball tickets ... late | Depositing money at Starbucks | Apple’s coming tweaks -
06/10/16 08:46 AMPreview of Analysts Recommendation: Cellectar Biosciences, Inc. (NASDAQ:CLRB) , ProNAi Therapeutics, Inc ... - Street Updates
06/10/16 08:46 AMBest Stocks for Investors: Baidu, Inc. (NASDAQ:BIDU), ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Beacon Chronicle
06/09/16 09:43 PMStock under Analyst' Radar: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/09/16 10:57 AMTwo Buzzers within Analysts Radar: Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) , ProNAi Therapeutics, Inc ... - Street Updates
06/08/16 08:27 PMAnalysts Suggestion Alert: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Street Updates
06/08/16 08:27 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ProNAi Therapeutics, Inc ... - PR Newswire (press release)
06/08/16 02:34 PMStock Analysis review: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - News Oracle
06/08/16 02:12 PMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ProNAi Therapeutics, Inc. (DNAI) - [PR Newswire] - NEW YORK, June 8, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of ProNAi Therapeutics, Inc. ...
06/08/16 09:21 AMPRONAI THERAPEUTICS INC. (NASDAQ:DNAI) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:46 PMProNAi Therapeutics Inc. (DNAI) Plunged After Development Of PNT2258 Suspended - RTT News
06/07/16 10:17 AMAnalyst Ratings on: ProNAi Therapeutics, Inc. (NASDAQ:DNAI), EMC Corporation (NYSE:EMC) - Beacon Chronicle
06/07/16 10:17 AMTwo Buzzers within Analysts Radar: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates
06/07/16 10:16 AMThis stock’s crash is a cautionary tale on the dangers of betting on biotech IPOs - It can be hard for investors and analysts to pick a winner in biotech. Investing in the initial public offerings of biotechnology companies can be a crapshoot. That may be the lesson for investors in ProNAi Therapeutics Inc. DNAI, +1.69% a biotechnology ...
06/06/16 03:53 PMIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against ProNAi Therapeutics, Inc. and Advises Investors to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by ProNAi Therapeutics, Inc. . The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
06/06/16 03:31 PMBuzz Stocks: Adamis Pharmaceuticals Corp, ProNAi Therapeutics Inc, and Juno Therapeutics Inc - Schaeffers Research (blog)
06/06/16 03:13 PMBiotech IPOs can be a crapshoot -
06/06/16 12:42 PMMonday's 7 Biggest Mid-Day Losers - ProNAi Therapeutics Inc (NASDAQ: DNAI) shares 65.78 percent to $2.18 in pre-market trading after the company reported interim data from Wolverine Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL). The company discontinued the development of DLBCL. Adamis Pharmaceuticals Corp (NASDAQ: ADMP) fell 53.61 percent to $4.11 in pre-market trading as the company revealed Monday it was advised by the FDA to expand its human study, as well as reliability student, i.e. product stress testing, to get its support for ...Full story available on Benzinga.com
06/04/16 09:40 AMRecent Analysts Rating Overview: ProNAi Therapeutics, Inc. (NASDAQ:DNAI) , United Therapeutics Corporation ... - Street Updates
06/03/16 03:49 PMProNAi Therapeutics, Inc. (DNAI) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/02/16 09:50 AMMerrill Lynch Picks ASCO Winners -
06/01/16 09:26 AMProNAi Therapeutics (DNAI) Names New Research SVP - StreetInsider.com - ProNAi Therapeutics (DNAI) Names New Research SVPStreetInsider.comProNAi Therapeutics, Inc. (Nasdaq: DNAI) announced it has appointed Dr. Christian Hassig as Senior Vice President, Research. Dr. Hassig will lead ProNAi's research activities from discovery research through to early candidate development. "Chris will ...ProNAi Therapeutics Appoints Dr. Christian Hassig as Senior Vice President of ResearchPR Newswire (press release)all 1 news articles »
06/01/16 06:13 AMProNAi Therapeutics Appoints Dr. Christian Hassig as Senior Vice President of Research - [at noodls] - VANCOUVER, June 1, 2016/CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted therapeutics, today announced it has appointed Dr. Christian Hassigas ...
05/27/16 01:39 PMProNAi Therapeutics (DNAI) Acquires Exclusive AS-141 Development, Commercialization License - StreetInsider.com - ProNAi Therapeutics (DNAI) Acquires Exclusive AS-141 Development, Commercialization LicenseStreetInsider.comProNAi Therapeutics, Inc. (Nasdaq: DNAI) announced it has obtained an exclusive license from Carna Biosciences, Inc., Kobe, Japan, for worldwide rights to develop and commercialize AS-141, a small molecule kinase inhibitor targeting CDC7.Are Analysts Bullish ProNAi Therapeutics Inc (NASDAQ:DNAI) After Last Week?The Postall 2 news articles »
05/27/16 08:02 AMPRONAI THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhi -
05/26/16 06:27 PMProNAi Licenses Cancer Drug Candidate Targeting CDC7 from Carna Biosciences - [at noodls] - - Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage response - VANCOUVER, May 26, 2016/CNW/ - ProNAi Therapeutics, ...
05/26/16 12:43 PMBroker Outlook For ProNAi Therapeutics, Inc. (DNAI) - Share Trading News - Broker Outlook For ProNAi Therapeutics, Inc. (DNAI)Share Trading NewsThe Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 ...Pronai Therapeutics Incorporated (NASDAQ:DNAI) Shorts Decreased by 10.36% After Short CoveringFranklin Independentall 2 news articles »
05/22/16 01:27 PMProNAi Therapeutics, Inc. (DNAI) Broker Price Targets For The Coming Week - Share Trading News - ProNAi Therapeutics, Inc. (DNAI) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ProNAi Therapeutics, Inc. (DNAI). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, ...
05/21/16 01:45 PMRecent Movements of Stocks: Nevro Corp. (NYSE:NVRO) , ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Street Updates - Recent Movements of Stocks: Nevro Corp. (NYSE:NVRO) , ProNAi Therapeutics, Inc. (NASDAQ:DNAI)Street UpdatesProNAi Therapeutics, Inc. (NASDAQ:DNAI) after beginning at $5.10, closed at $5.37 by building up +7.40% in recent trading session. Most recent session's volume of 497.76 thousand shares greater than its average volume of 148.88 thousand shares.and more »
05/20/16 01:42 PMHere's What To Look Out For In The Upcoming ProNAi Therapeutics Inc (NASDAQ:DNAI) Data - Market Exclusive - Market ExclusiveHere's What To Look Out For In The Upcoming ProNAi Therapeutics Inc (NASDAQ:DNAI) DataMarket ExclusiveProNAi Therapeutics Inc (NASDAQ:DNAI) just reported that it is set to deliver interim results from an ongoing phase II in its lead oncology candidate at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). The event is scheduled ...ProNAi Therapeutics, Inc. (DNAI) - Broker UpdateRisers & FallersCan ProNAi Therapeutics (DNAI) Keep the Earnings Streak Alive This Quarter?NasdaqBroker Roundup For ProNAi Therapeutics, Inc. (DNAI)Share Trading NewsThe Post -News Oracle -Wall Street Hints and Newsall 10 news articles »
05/20/16 07:00 AMPronai Therapeutics (DNAI) Shows Strength: Stock Rises 7.4% -
05/19/16 01:53 PMHere’s What To Look Out For In The Upcoming ProNAi Therapeutics Inc (NASDAQ:DNAI) Data - ProNAi Therapeutics Inc (NASDAQ:DNAI) just reported that it is set to deliver interim results from an ongoing phase II in its lead oncology candidate at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). The event is scheduled to ...
05/18/16 05:12 PMProNAi to Report Wolverine Phase 2 Interim Results on June 6th at ASCO - [at noodls] - - ProNAi to hold Analyst & Investor Event at 7:00am CTon June 6- - ProNAi to Present at Jefferies 2016 Healthcare Conference in New Yorkon June 9- VANCOUVER, May 18, 2016/CNW/ - ProNAi Therapeutics, Inc. ...
05/18/16 01:32 PMProNAi Therapeutics Inc (NASDAQ:DNAI) PT analysis - News Oracle - ProNAi Therapeutics Inc (NASDAQ:DNAI) PT analysisNews OracleThe company is currently showing ROA (Return on Assets) value of -366.10%.By looking at ProNAi Therapeutics Inc (NASDAQ:DNAI) YTD (year to date) performance, the stock shows Negative value of -65.76%. If the YTD value is Negative, it means that the ...
About ProNAi Therapeutics

ProNAi Therapeutics logoProNAi Therapeutics, Inc. is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer. The Company's PNT2258 is a formulation of its single-stranded 24-base DNAi oligonucleotide, known as PNT100, encapsulated in the SMARTICLES Lipid Nanoparticle (LNP). The Company's PNT2258 consists of over two components, including PNT100 DNAi Oligonucleotide and LNP Delivery Technology. It has conducted over two clinical trials for PNT2258, which include a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DNAI
  • CUSIP:
Key Metrics:
  • Previous Close: $1.97
  • 50 Day Moving Average: $4.06
  • 200 Day Moving Average: $7.48
  • P/E Ratio: N/A
  • P/E Growth: -0.02
  • Market Cap: $59.44M
  • Current Quarter EPS Consensus Estimate: $-1.46 EPS
Additional Links:
ProNAi Therapeutics (NASDAQ:DNAI) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha